Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results
Rhea-AI Summary
Apyx Medical (Nasdaq: APYX) reported preliminary, unaudited revenue for Q4 and full year 2025. Q4 2025 total revenue is expected to be approximately $19.0–$19.2M (+~34% YoY), driven by Surgical Aesthetics of $16.6–$16.8M (+~38% YoY) and OEM revenue of ~$2.4M (+~13% YoY). Apyx cited a U.S. Surgical Aesthetics increase of ~51% following the AYON commercial launch. For full year 2025, total revenue is expected at $52.7–$52.9M (+~10% YoY), Surgical Aesthetics $45.2–$45.4M (+~17% YoY), and OEM ~$7.5M (−21% YoY). The company will release audited results in March 2026; figures are preliminary and subject to closing and audit procedures.
Positive
- Q4 total revenue expected +34% year-over-year to $19.0–$19.2M
- Q4 Surgical Aesthetics revenue expected +38% year-over-year to $16.6–$16.8M
- Full-year 2025 Surgical Aesthetics revenue expected +17% to $45.2–$45.4M
- U.S. Surgical Aesthetics revenue increased approximately 51% after AYON launch
Negative
- Full-year 2025 OEM revenue expected −21% year-over-year to ~$7.5M
News Market Reaction – APYX
In the Jan 12 session, APYX gained 14.90%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.7% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.2x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Intl launch/approval | Positive | -1.7% | MFDS approval and commercial launch of Apyx One in South Korea. |
| Nov 18 | Equity offering priced | Negative | -5.5% | Pricing of $10M underwritten public offering of common stock. |
| Nov 17 | Equity offering proposed | Negative | +3.3% | Announcement of proposed underwritten public offering from existing shelf. |
| Nov 06 | Earnings update | Positive | +6.7% | Q3 2025 results with revenue growth, margin expansion, narrowed losses. |
| Oct 27 | Investor conferences | Neutral | -2.5% | Planned participation in November investor conferences in New York. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The stock has tended to react positively to strong operating updates but has shown mixed responses to international launches and capital-raising announcements.
Over the last few months, APYX reported improving fundamentals, with Q3 2025 revenue of $12.9M, higher gross margins, and narrowed losses, alongside the U.S. launch of the AYON Body Contouring System. Subsequent news included proposed and priced equity offerings and MFDS approval plus launch of Apyx One in South Korea. Today’s preliminary 2025 revenue update extends that narrative of Surgical Aesthetics growth following AYON’s rollout and earlier international expansion.
Key Terms
GLP-1 therapies medical
forward-looking statements regulatory
U.S. Food and Drug Administration regulatory
Annual Report on Form 10-K regulatory
Securities and Exchange Commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Surgical Aesthetics revenue increased approximately
CLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2025.
Preliminary Fourth Quarter 2025 Revenue Summary:
- Total revenue is expected to be in the range of approximately
$19.0 t o$19.2 million , representing an increase of approximately34% year-over-year.- Surgical Aesthetics revenue is expected to be in the range of approximately
$16.6 t o$16.8 million , representing an increase of approximately38% year-over-year. - OEM revenue is expected to be approximately
$2.4 million , representing an increase of approximately13% year-over-year.
- Surgical Aesthetics revenue is expected to be in the range of approximately
Preliminary Full Year 2025 Revenue Summary:
- Total revenue is expected to be in the range of approximately
$52.7 t o$52.9 million , representing an increase of approximately10% year-over-year.- Surgical Aesthetics revenue is expected to be in the range of approximately
$45.2 t o$45.4 million , representing an increase of approximately17% year-over-year. - OEM revenue is expected to be approximately
$7.5 million , representing a decrease of21% year-over-year.
- Surgical Aesthetics revenue is expected to be in the range of approximately
“We are excited by AYON’s commercial launch, which delivered immediate momentum and contributed to a strong fourth quarter, including an increase of approximately
This press release includes Apyx Medical Corporation’s preliminary revenue results for the quarter and full year ended December 31, 2025. Apyx Medical plans to release its fourth quarter and full year 2025 financial results in March 2026. Actual fourth quarter and full year 2025 revenue results are subject to completion of the Company’s year-end financial closing procedures and year-end audit procedures by the Company’s independent registered public accounting firm.
Investor Relations Contact:
Jeremy Feffer, Managing Director LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About Apyx Medical Corporation:
Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring SystemTM in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, statements regarding the Company’s anticipated public offering, including the completion of the public offering on the anticipated terms and the use of proceeds therefrom, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.
Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
